Sign in26 stories
New Phase 1 lung cancer data, early CONVERGE efficacy signals, and a NANORAY-312 protocol amendment accompanied a first half 2026 financial report showing €110.9 million in cash.
SEC filing
JNJ-5120/PIPE-307, licensed to Johnson & Johnson, missed its primary efficacy measure in major depressive disorder, though the company reported no new safety signals.
SEC filing
The MASH drug developer said Benecchi will oversee launch preparations for lanifibranor ahead of Phase 3 data expected in the fourth quarter of 2026.
SEC filing
The clinical-stage biopharma named Craig L. Tendler, M.D., a former Johnson & Johnson oncology leader, as a new Class II director on August 22, 2026.
SEC filing
Cybin's commercial unit Helus Pharma added a Chief People Officer and a Scientific Advisory Board member, both formerly of Intra-Cellular Therapies.
SEC filing (2)
The two appointments, effective August 13, 2026, rebalance board classes as Maze advances its kidney and metabolic disease pipeline toward late-stage development.
SEC filing
The company completed the bota-vec acquisition from J&J, finished enrollment in its pivotal AQUAx2 study, and secured up to $400 million from Oberland Capital.
SEC filing
The former Intra-Cellular Therapies president takes over as topline data from the first pivotal study of HLP003 in major depressive disorder are expected in the fourth quarter of 2026.
SEC filing (2)
Protagonist reported $162.8 million net income for the quarter, driven by Takeda payments, while awaiting an FDA decision on rusfertide in August 2026.
SEC filing
Johnson & Johnson said Jennifer Taubert is stepping down after more than two decades at the company, with Tom Cavanaugh taking over effective September 1, 2026.
SEC filing
The biopharmaceutical company expanded its board to five members, adding a former Johnson & Johnson licensing and M&A executive effective August 3, 2026.
SEC filing
Contineum said its Phase 2 PROPEL-IPF trial for PIPE-791 is expanding sites while partner Johnson & Johnson finished enrolling its Phase 2 depression trial of JNJ-5120/PIPE-307.
SEC filing
The deal adds Firefly's degrader antibody conjugate platform aimed at KRAS-driven cancers and will cut J&J's 2026 adjusted EPS by about $0.46.
SEC filing
The company reported second-quarter reported sales of $25.3 billion and lifted its full-year outlook, citing regulatory approvals and pipeline data across Innovative Medicine and MedTech.
SEC filing
The appointment took effect July 13, 2026, with a base salary of $445,000 and stock options for 800,000 shares.
SEC filing